D.E. Shaw & Co
TARO

D.E. Shaw & Co’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

D.E. Shaw & Co’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,000
Closed -$282K – 3909
2015
Q1 		$282K Hold
2,000
– – ﹤0.01% 3330
2014
Q4 		$296K Hold
2,000
– – ﹤0.01% 3648
2014
Q3 		$308K Buy
+2,000
New +$301K ﹤0.01% 3678

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

D.E. Shaw & Co's TARO Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2024, closing a stake of 10,345 shares — an estimated $432K sold.

D.E. Shaw & Co first reported a position in TARO in Q2 2013 and held it in 34 quarters. The position peaked at $8.11M in Q4 2019. 94 funds tracked by Wall St. Rank hold TARO as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,345 Taro Pharmaceutical Industries Ltd. shares in Q1 2024, an estimated $432K.
  • D.E. Shaw & Co first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2013 and held it in 34 quarters.
  • D.E. Shaw & Co's Taro Pharmaceutical Industries Ltd. position peaked at $8.11M in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.